

Transparency Information

Leuven (BELGIUM) – February 12, 2010 – TiGenix (NYSE EURONEXT BRUSSELS: TIG) publishes the information in accordance with articles 15, 18 and 29 of the Belgian Act of May 2, 2007 and the Royal Decree of February 14, 2008, regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated Belgian market.

TiGenix has received a notification with regard to the participation in TiGenix NV of ING Group NV, having its registered office at Amstelveenseweg 500, 1081 KL Amsterdam, the Netherlands.

As a result of a transfer of securities carrying voting rights, ING Group NV manages a participation in TiGenix NV of 13.78% which lies below the threshold of 15%, out of an aggregate amount of 30,866,168 securities carrying voting rights in TiGenix NV.

Further details on the transparency notifications and major shareholding in TiGenix NV can be found on TiGenix' website www.tigenix.com.

For more information, please contact:

Frank Hazevoets
Chief Financial Officer

T: +32 16 39 60 60
investor@tigenix.com

About TiGenix

Based in Leuven, Belgium, TiGenix NV (NYSE Euronext Brussels: TIG) is a biomedical company that focuses on 'Regenerating Motion'. The company is exploiting the power of Regenerative Medicine to develop durable treatments, validated through controlled clinical trials, for damaged and osteoarthritic joints.

TiGenix is developing a portfolio of products that address specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction affecting the mobility and functioning of patients. Western societies are characterised by ageing populations that place an increasing emphasis on high quality of life and life-long mobility, and, as such, cartilage problems represent a large and growing unmet medical need. Current therapies do not provide satisfying, long-term durable repair and TiGenix therefore believes there is a need for more effective treatments for cartilage damage.

ChondroCelect[®], the company's lead product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, over clinical development to central European registration as a medicinal product. On October 5, 2009 ChondroCelect[®] received European marketing authorisation as the first approved Advanced Therapy Medicinal Product (ATMP).

Forward-looking information

This document contains forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.